Actively Recruiting
Integrating Pediatric Pharmacogenomic Testing Into the Canadian Health Care System
Led by University of British Columbia ยท Updated on 2026-05-01
150
Participants Needed
2
Research Sites
N/A
Total Duration
On this page
Sponsors
U
University of British Columbia
Lead Sponsor
G
Genome British Columbia
Collaborating Sponsor
AI-Summary
What this Trial Is About
This research focuses on addressing adverse drug reactions in children taking three common types of medications: antibiotics, pain relievers, and mental health drugs. The study aims to test a pharmacogenomic panel that helps predict how these medications might affect individual patients. Researchers will also explore how doctors, pharmacists, patients, and families understand and use these test results. The study involves implementing a pilot program for pharmacogenomic testing to improve medication safety and effectiveness. Data collection forms will be created to gather information from prescribing physicians. Pharmacogenomic reports will be developed to share test results with healthcare providers, patients, and their families. The study will assess the perceptions and use of these tests and reports by all involved parties. Participants will be monitored to provide pharmacogenomic recommendations about the risk of gene-related adverse events before or during treatment with analgesics, antibiotics, or mental health medications. A total of 150 participants will be involved. The study will collect information on how the test results influence medication decisions and safety. Participation may last as long as needed to gather this information, with ongoing communication and data collection from healthcare providers and families.
CONDITIONS
Brief Title
Integrating Pediatric Pharmacogenomic Testing Into the Canadian Health Care System
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants will be enrolled if they can benefit from pharmacogenomic testing. This means their physician is considering the use of a drug that is part of the panels (analgesics, antibiotics, and mental health medication) or they are already using one.
You will not qualify if you...
- Patients who do not speak or understand English.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 8 years
Participants are observed to understand how pharmacogenomic testing results are perceived and utilized by physicians, pharmacists, patients, and their families.
Participants have pharmacogenomic recommendations provided prior to or during treatment with analgesics, anti-infectives, or psychotropics.
Trial Site Locations
Total: 2 locations
1
Children's and Women's Health Centre of British Columbia
Vancouver, British Columbia, Canada, V6H 3V4
Actively Recruiting
2
Children's Hospital of Eastern Ontario
Ottawa, Ontario, Canada, K1H 8L1
Actively Recruiting
Research Team
B
Bruce Carleton, PharmD.
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here